These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23950174)

  • 1. CMV: a warrior against leukemia?
    Ljungman P
    Blood; 2013 Aug; 122(7):1101-2. PubMed ID: 23950174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
    Green ML; Leisenring WM; Xie H; Walter RB; Mielcarek M; Sandmaier BM; Riddell SR; Boeckh M
    Blood; 2013 Aug; 122(7):1316-24. PubMed ID: 23744585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.
    Yoon JH; Lee S; Kim HJ; Jeon YW; Lee SE; Cho BS; Lee DG; Eom KS; Kim YJ; Min CK; Cho SG; Min WS; Lee JW
    Oncotarget; 2016 Mar; 7(13):17230-41. PubMed ID: 26883100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytomegalovirus reactivation after allogeneic stem cell transplantation reduces the risk of relapse in patients with acute myeloid leukemia].
    Takenaka K
    Rinsho Ketsueki; 2015 Jul; 56(7):825-30. PubMed ID: 26251145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.
    Litjens NHR; van der Wagen L; Kuball J; Kwekkeboom J
    Front Immunol; 2018; 9():389. PubMed ID: 29545802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
    Verduyn Lunel FM; Raymakers R; van Dijk A; van der Wagen L; Minnema MC; Kuball J
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1883-1887. PubMed ID: 27470287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
    Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
    Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation.
    Morita-Hoshi Y; Heike Y; Kawakami M; Sugita T; Miura O; Kim SW; Mori SI; Fukuda T; Tanosaki R; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2008 Mar; 41(6):515-21. PubMed ID: 18026143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
    Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
    Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Lee SM; Kim YJ; Yoo KH; Sung KW; Koo HH; Kang ES
    Ann Lab Med; 2017 May; 37(3):277-281. PubMed ID: 28224776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
    Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytomegalovirus infection after haploidentical stem cell transplantation may reduce relapse risk in leukemia].
    Lin X; Ou Y; Long H; Huang Y; Song C; Lu Z; Guo K; Wu B; Xu J
    Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):107-10. PubMed ID: 26875578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analyses of leukemia-associated antigen-specific CD8
    Rücker-Braun E; Link CS; Schmiedgen M; Tunger A; Vizjak P; Teipel R; Wehner R; Kühn D; Fuchs YF; Oelschlägel U; Germeroth L; Schmitz M; Bornhäuser M; Schetelig J; Heidenreich F
    Exp Hematol; 2016 Nov; 44(11):1024-1033.e1. PubMed ID: 27473564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
    Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.